Brief: Wilex says unit Heidelberg Pharma signs research agreement with Takeda

Heidelberg Pharma AG

19/06/2017 16:14

June 19 (Reuters) - WILEX AG  WL6G.DE : 
    * SUBSIDIARY HEIDELBERG PHARMA SIGNS EXCLUSIVE MULTI-TARGET 
RESEARCH AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT OF ANTIBODY 
TARGETED AMANITIN CONJUGATES 
    * UNDER TERMS OF AGREEMENT, HEIDELBERG PHARMA WILL PRODUCE 
ANTIBODY TARGETED AMANITIN CONJUGATES (ATACS) USING ANTIBODIES 
FROM TAKEDA'S PROPRIETARY PORTFOLIO FOR UP TO THREE UNDISCLOSED 
TARGETS 
    * UNDER LICENSE AGREEMENT, HEIDELBERG PHARMA WOULD BE 
ELIGIBLE TO RECEIVE CLINICAL DEVELOPMENT, REGULATORY AND 
SALES-RELATED MILESTONE PAYMENTS OF UP TO USD 113 MILLION FOR 
EACH PRODUCT CANDIDATE, AS WELL AS ROYALTIES 
 
Source text for Eikon:  ID:nEQ38l9LRa  
Further company coverage:  WL6G.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))